By Ethan Covey
Despite the fact that Merck’s Zostavax shingles vaccine provides seniors with high rates of protection from the herpes zoster virus, use of the vaccine remains low, according to a new FDA study.
MARCH 30, 2017
MARCH 30, 2017
By Ethan Covey
Despite the fact that Merck’s Zostavax shingles vaccine provides seniors with high rates of protection from the herpes zoster virus, use of the vaccine remains low, according to a new FDA study.